This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Anecortave
- DrugBank Accession Number
- DB12081
- Background
Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Anecortave (DB12081)
- Weight
- Average: 344.451
Monoisotopic: 344.198759382 - Chemical Formula
- C21H28O4
- Synonyms
- Not Available
- External IDs
- AL 4940
- AL-4940
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Alendronic acid. Clodronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Clodronic acid. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Anecortave. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Anecortave. Etidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Etidronic acid. Ibandronate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Ibandronate. Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Anecortave. Pamidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Pamidronic acid. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Anecortave. Risedronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Anecortave is combined with Risedronic acid. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- S01LA02 — Anecortave
- Drug Categories
- 11-Hydroxycorticosteroids
- 17-Hydroxycorticosteroids
- Adrenal Cortex Hormones
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Antineoplastic Agents
- Antineovascularisation Agents
- Fused-Ring Compounds
- Growth Inhibitors
- Growth Substances
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hydroxycorticosteroids
- Ocular Vascular Disorder Agents
- Ophthalmologicals
- Pregnanes
- Pregnenediones
- Pregnenes
- Sensory Organs
- Steroids
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Hydroxysteroids
- Direct Parent
- 21-hydroxysteroids
- Alternative Parents
- Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxosteroids / 17-hydroxysteroids / Cyclohexenones / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic alcohols and derivatives / Primary alcohols / Organic oxides show 1 more
- Substituents
- 17-hydroxysteroid / 20-oxosteroid / 21-hydroxysteroid / 3-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Alpha-hydroxy ketone / Carbonyl group / Cyclic alcohol / Cyclic ketone show 11 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R5Y8O51589
- CAS number
- 10184-70-0
- InChI Key
- BCFCRXOJOFDUMZ-ONKRVSLGSA-N
- InChI
- InChI=1S/C21H28O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h6,11,15,17,22,25H,3-5,7-10,12H2,1-2H3/t15-,17+,19+,20+,21+/m1/s1
- IUPAC Name
- (2S,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1(17),6-dien-5-one
- SMILES
- C[C@]12CC=C3[C@@H](CCC4=CC(=O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
References
- General References
- Not Available
- External Links
- PubChem Compound
- 7074810
- PubChem Substance
- 347828387
- ChemSpider
- 5428328
- ChEMBL
- CHEMBL2348782
- ZINC
- ZINC000003927675
- Wikipedia
- Anecortave_acetate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0334 mg/mL ALOGPS logP 2.98 ALOGPS logP 2.18 ChemAxon logS -4 ALOGPS pKa (Strongest Acidic) 12.58 ChemAxon pKa (Strongest Basic) -3.3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 74.6 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 96.66 m3·mol-1 ChemAxon Polarizability 38.24 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:19 / Updated at June 12, 2020 16:53